Advertisement

Featured in NEJM Journal Watch: Once-Weekly Therapy of Skin and Soft-Tissue Infections — Physician’s First Watch

Medical News |
June 5, 2014

Featured in NEJM Journal Watch: Once-Weekly Therapy of Skin and Soft-Tissue Infections

By the NEJM Journal Watch Editors

Both dalbavancin and oritavancin proved efficacious in clinical trials in the New England Journal of Medicine. In NEJM Journal Watch Infectious Diseases, Dr. Larry M. Baddour writes that adoption of these drugs "could dramatically change the outpatient management" of skin and soft-tissue infections.

Reader Comments (3)

Liane Bottino Physician, Gastroenterology, Rio de Janeiro, Brazil

This is an important daily activity to me to follow your information.

Almetrek, MBBS,MD,PMP Physician, Family Medicine/General Practice, Saudi Arabia

Is there any outcome of of the treatment and recurrence for skin and soft tissue abscess was studied?
If NOT we need to look for evidence to give us the answer.

Thanks

Katherine Parrish FNP Other Healthcare Professional, Family Medicine/General Practice, Elon University-retired

I enjoy keeping up with new information and journals like yours are a great way to do this in my time.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement